SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

KT, just a comment related to your post

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
JamesGMS Member Profile
 
Followed By 29
Posts 312
Boards Moderated 0
Alias Born 02/15/05
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 7/21/2017 4:12:16 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 7/20/2017 4:21:29 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) "Edgar (US Regulatory)" - 7/20/2017 12:43:22 PM
Ronin Trading and SW Investment Management Issue Letter to Employees of Peregrine Pharmaceuticals "PR Newswire (US)" - 7/20/2017 8:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/14/2017 4:49:23 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 7/14/2017 4:31:03 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 7/14/2017 4:28:39 PM
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments "GlobeNewswire Inc." - 7/14/2017 4:14:02 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 7/14/2017 7:53:56 AM
Peregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Management’s Letter to Stockholders "GlobeNewswire Inc." - 7/13/2017 6:08:59 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) "Edgar (US Regulatory)" - 7/13/2017 5:01:34 PM
Ronin Trading and SW Investment Management Issue Letter to Stockholders of Peregrine Pharmaceuticals "PR Newswire (US)" - 7/13/2017 8:55:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/7/2017 5:05:55 PM
Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017 "GlobeNewswire Inc." - 7/7/2017 4:05:00 PM
Peregrine Pharmaceuticals Announces Reverse Stock Split "GlobeNewswire Inc." - 7/7/2017 10:25:00 AM
Announcing VanEck Vectors Equity ETF’s June 2017 Distributions "Business Wire" - 6/30/2017 5:27:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 6/29/2017 5:26:08 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 6/20/2017 5:27:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:33:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/6/2017 4:26:06 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 6/6/2017 4:05:00 PM
Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017 "GlobeNewswire Inc." - 6/5/2017 8:05:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 5/19/2017 4:36:33 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/28/2017 7:00:04 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/28/2017 6:58:33 PM
JamesGMS   Monday, 07/17/17 07:31:27 PM
Re: keep_trying post# 304172
Post # of 305208 
KT, just a comment related to your post excerpted in relevant part below:

Quote:
Oops, the faction on Item T was for that Phase 2 study where the dose switching left PPHM retail shareholders "at the altar" after the run up to over $5 1/2 pps, pre split.

The Phase 3 trial halt was on its own path. There were at least three unusual trial results related events that left expectations for PPHM successful commercialization with a set back, by my recollection:

1. the unusual control group performance that showed the placebo group outperforming previous trial control groups by a large margin. . . . . . . . .



The Phase III result was particularly difficult as Garnick et al were highly confident of an approval - most likely after the second look, and, as reiterated to me once again by a close associate of Dr. Garnick just last week, Bavi did indeed perform exactly as expected - actually better than Opdivo in a very similar trial - which really made our result that much more difficult to understand. Dr. Garnick did his job - Bavi should have been approved last year.

Enjoy your evening.

James


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist